Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2004
Exchange: NASDAQ
Website: alnylam.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2026 | $380.00 | Buy | Citigroup |
| 3/16/2026 | $330.00 | Buy → Hold | Jefferies |
| 1/28/2026 | $527.00 | Overweight | Barclays |
| 1/7/2026 | $500.00 | Outperform | Oppenheimer |
| 8/4/2025 | Underperform → Peer Perform | Wolfe Research | |
| 8/4/2025 | $490.00 | Perform → Outperform | Oppenheimer |
| 7/30/2025 | $370.00 | Outperform | Raymond James |
| 7/21/2025 | $385.00 | Buy | Truist |
| 3/31/2025 | $353.00 | Buy | Redburn Atlantic |
| 3/24/2025 | $280.00 → $328.00 | Neutral → Overweight | Analyst |
Fastest customizable press release news feed in the world
− Collaboration is valued at up to $2B with upfront consideration of $30M − − Alliance pairs Alnylam's RNAi platform and 20+ years of proprietary data with Inceptive's foundation models and AI expertise to catalyze progress beyond rational drug design – − Partnership designed to accelerate timelines and unlock innovative oligonucleotide designs − Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cas
USA News Group News CommentaryIssued on behalf of Avaí Bio, Inc.As the broader cell and gene therapy complex posts record quarterly revenue and advances toward accelerated approval pathways, a Nevada-based longevity joint venture has just cleared a manufacturing-stage gate on its α-Klotho anti-aging program.NEW YORK, May 28, 2026 /CNW/ -- Cell and gene therapy has crossed a meaningful inflection in 2026. Vertex Pharmaceuticals reported Q1 product revenue of $2.99 billion, with newer non-CF franchises CASGEVY and JOURNAVX contributing more than 25% of year-over-year growth. Alnylam Pharmaceuticals delivered its first-ever $1 billion product revenue quarter. Beam Therapeutics presented updated
– Published Scope 1 and Scope 2 Greenhouse Gas (GHG) Emissions Reduction Framework through 2030 – – Expanded Global Patient Access and Support – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected throughout the report is the global theme, "Accepting Challenges to Improve the Health of Humanity," which remains central to Alnylam's strategy and is embedded across six interconnected pillars that guide the company's work: Patients, Science, Employees,
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies – − Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering – − DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida. A live audio webcast of each presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. Replays will be available on the Alnylam website within 48 hours after each event. About Alnylam Pharmaceuticals Alnylam (NASDAQ:ALNY) is
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients w
− Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million (121% Growth Compared with Q1 2025), Driven Primarily by Total TTR Revenues of $910 Million (153% Growth Compared with Q1 2025) – − Reiterates 2026 Financial Guidance, Including Combined Net Product Revenues of $4,900 Million to $5,300 Million, and Total TTR Net Product Revenues of $4,400 to $4,700 Million – − New Data Presented at ACC.26 Further Support Use of Vutrisiran as First-Line Treatment for ATTR-CM – − Established Collaborations with Viz.ai and AHA Focused on Earlier Diagnosis, Coordinated Care and Long-Term Patient Impact in ATTR-CM – − Deep Pipeline Progressing Toward Multiple Clinical Readouts Du
AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, s
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday, April 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2026 results as well as expectations for the future via conference call on Thursday, April 30, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceut
− Vutrisiran, which Silences Transthyretin at the Source, Shown to Improve Health-Related Quality-of-Life in Those with ATTR-CM, with Treatment Effects Comparable to Patients More than Ten Years Younger – − Findings Reinforce Consistent Benefits of Vutrisiran Across ATTR-CM Disease Spectrum, Including Patients with Most Advanced Disease and Diastolic Dysfunction − − Real-World Data Demonstrate High Adherence and Persistence of Quarterly HCP-Administered Dosing with Vutrisiran – − Pooled Phase 2 Safety Data Reinforce Encouraging Safety Profile for Zilebesiran Across a Broad Population of Patients with Hypertension − Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therap
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup initiated coverage of Alnylam Pharma with a rating of Buy and set a new price target of $380.00
Jefferies downgraded Alnylam Pharma from Buy to Hold and set a new price target of $330.00
Barclays resumed coverage of Alnylam Pharma with a rating of Overweight and set a new price target of $527.00
Oppenheimer resumed coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $500.00
Wolfe Research upgraded Alnylam Pharma from Underperform to Peer Perform
Oppenheimer upgraded Alnylam Pharma from Perform to Outperform and set a new price target of $490.00
Raymond James resumed coverage of Alnylam Pharma with a rating of Outperform and set a new price target of $370.00
Truist initiated coverage of Alnylam Pharma with a rating of Buy and set a new price target of $385.00
Redburn Atlantic initiated coverage of Alnylam Pharma with a rating of Buy and set a new price target of $353.00
Analyst upgraded Alnylam Pharma from Neutral to Overweight and set a new price target of $328.00 from $280.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
SCHEDULE 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
DEFA14A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
DEF 14A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
SCHEDULE 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-5) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 212194, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug ONPATTRO (SUPPL-12) with active ingredient PATISIRAN SODIUM has changed to 'Approval' on 01/13/2023. Application Category: NDA, Application Number: 210922, Application Classification: Efficacy
Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-3) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 10/06/2022. Application Category: NDA, Application Number: 214103, Application Classification: Efficacy
Submission status for ALNYLAM PHARMS INC's drug ONPATTRO (SUPPL-13) with active ingredient PATISIRAN SODIUM has changed to 'Approval' on 10/03/2022. Application Category: NDA, Application Number: 210922, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug ONPATTRO (SUPPL-13) with active ingredient PATISIRAN SODIUM has changed to 'Approval' on 10/04/2022. Application Category: NDA, Application Number: 210922, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (ORIG-1) with active ingredient VUTRISIRAN has changed to 'Approval' on 06/13/2022. Application Category: NDA, Application Number: 215515, Application Classification: Type 1 - New Molecular Entity
Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-4) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 10/28/2021. Application Category: NDA, Application Number: 212194, Application Classification: Labeling
Live Leadership Updates
– Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and Carolyn Bertozzi, Ph.D., who have served in key roles on Alnylam's Board, stepped down effective December 2, 2025. Mr. Bonney joined our Board in 2014 and served as Board Chair from December 2015 to August 2021 and as Executive Chair from August 2021 to January 2023. He helped to guide the company through major milestones and significant growt
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the retirement of Dr. Phillip A. Sharp, Ph.D., from the Company's Board of Directors, effective as of May 8, 2025. Dr. Sharp has served as a key advisor to Alnylam since he co-founded the Company in 2002. Dr. Sharp will remain a member of the Alnylam Scientific Advisory Board. "Phil helped pioneer the RNAi revolution, sparking the scientific collaboration that led to Alnylam's founding and the development of a transformative new class of medicines," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "He has provided invaluable guidance over the past twenty-two years that has
As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th
– Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi
– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 35% Annual Growth (43% Using Constant Exchange Rate**) – – Strength of AMVUTTRA Launch Drove 37% Total TTR Annual Revenue Growth – – Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of Approximately $2.2 Billion – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products' commercial launches. Preliminary Four
– Appoints Carolyn Bertozzi, Ph.D., Nobel Laureate and Leading Voice for Chemical Biology, Emerging Technology, and Life Sciences Companies – – Michael W. Bonney Steps Down as Executive Chair and Continues on Board as Non-Independent Director – – Amy W. Schulman will Assume Role of Chair of the Board – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, today announces appointment of Carolyn Bertozzi, Ph.D. a Nobel Laureate to the Board. Dr. Bertozzi is known is known for her work in chemical biology. She is a pioneer for emerging technology and has founded ten biopharmaceutical companies and guided more than a dozen academic and professional organizations
– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical Trial Authorization (CTA) application to Health Canada to initiate a Phase 1/2 study of ALN-KHK, an investigational RNAi therapeutic targeting ketohexokinase (KHK) for the treatment of Type 2 diabetes mellitus (T2DM). Pending regulatory authority and ethic committee approvals, the Company plans to begin enrollment in a Phase 1/2 study in healthy overweight to obese volunteers and obese patients with T2DM in early
− Product and Pipeline Goals Detail Execution across Four Commercial Brands, Including One Potential Label Expansion, and Ten Clinical Data Readouts From Proprietary and Partner Programs – − Pipeline Programs and Scientific Innovation Highlighted at R&D Day Exemplify Strength of RNAi Platform and Organic Product Engine – − Alnylam to Webcast its R&D Day Event Today at 8:30 a.m. ET – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2023 focused on continued commercial execution of four
– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 – – Study Also Demonstrated Encouraging Safety Profile in Patients with Cardiomyopathy of ATTR Amyloidosis – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the submission of its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Patisira
Live finance-specific insights
− Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million (121% Growth Compared with Q1 2025), Driven Primarily by Total TTR Revenues of $910 Million (153% Growth Compared with Q1 2025) – − Reiterates 2026 Financial Guidance, Including Combined Net Product Revenues of $4,900 Million to $5,300 Million, and Total TTR Net Product Revenues of $4,400 to $4,700 Million – − New Data Presented at ACC.26 Further Support Use of Vutrisiran as First-Line Treatment for ATTR-CM – − Established Collaborations with Viz.ai and AHA Focused on Earlier Diagnosis, Coordinated Care and Long-Term Patient Impact in ATTR-CM – − Deep Pipeline Progressing Toward Multiple Clinical Readouts Du
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2026 on Thursday, April 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2026 results as well as expectations for the future via conference call on Thursday, April 30, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceut
− Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – − Attained GAAP and non-GAAP Profitability for Full Year 2025, with Sustainable Growth in Operating Income Expected – − Launched "Alnylam 2030" Strategy Focused on Scaling Alnylam through Durable ATTR Leadership, Long-Term Sustainable Innovation, and Exceptional Financial Results – − Announced 2026 Pipeline Goals, Including 4 Clinical Readouts, 3 Ongoing Pivotal Studies, 3 Phase 2 Study Initiations, and 3+ New IND Filings – − Reiterates Net Product Sales Guidance and Provides Additional 2026 Fin
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2025 on Thursday, February 12, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2025 results as well as expectations for the future via conference call on Thursday, February 12, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025. The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Ferrovial SE (NASDAQ:FER), Insmed Incorporated (NASDAQ:INSM), Monolithic Power Systems, Inc. (NASDAQ:MPWR), Seagate Technology Holdings plc (NASDAQ:STX), Western Digital Corp. (NASDAQ:WDC). The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies listed on the Nasdaq Stock Market® encompassi
− Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) – − Continued Broad Access and Balanced Utilization of AMVUTTRA Across All ATTR-CM Patient Segments – − Presented New Data from the HELIOS-B Phase 3 Study at Major Congresses Demonstrating Vutrisiran's Long-Term Cardiovascular Benefit and Lower Rates of Gastrointestinal Events in ATTR-CM – − Advanced Multiple Pipeline Programs, Including Two New Phase 3 Trials, ZENITH for Zilebesiran in Hypertension, and TRITON-PN for Nucresiran in hATTR-PN – − Raises 2025 Guidance for TTR Franchise Net Revenues
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2025 results as well as expectations for the future via conference call on Thursday, October 30, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Ph
− Generated Q2 2025 Total Net Product Revenues of $672 Million (64% Growth Compared with Q2 2024), Driven Primarily by Total TTR Revenues of $544 Million (77% Growth Compared with Q2 2024) – − Achieved Approximately 1,400 ATTR-CM Patients on AMVUTTRA® (vutrisiran) as of June 30, 2025 – − Obtained Approvals for AMVUTTRA for the Treatment of ATTR-CM in the European Union, Brazil, the United Kingdom and Japan – − Initiated TRITON-CM Phase 3 Trial of Nucresiran in Patients with Wild-Type or Hereditary ATTR-CM – − Raises 2025 Guidance for TTR Franchise Net Revenues to $2,175 Million to $2,275 Million; Total Net Product Revenues to $2,650 Million to $2,800 Million, Representing a $575 Mil
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2025 on Thursday, July 31, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2025 results as well as expectations for the future via conference call on Thursday, July 31, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Pharmaceuti
− Achieved First Quarter 2025 Global Net Product Revenues of $469 Million, Representing 28% Year-Over-Year Growth Compared to Q1 2024 Driven by Continued Strong Growth of 36% from hATTR-PN Franchise – − Received U.S. Food and Drug Administration (FDA) Approval of AMVUTTRA® (vutrisiran) to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) – − AMVUTTRA ATTR-CM Launch Underway with Strong Progress Across All Early Commercial Indicators – − Approval of Qfitlia™ Represents the First and Only Therapeutic to Treat Hemophilia A or B With or Without Inhibitors and the Sixth Alnylam-Discovered
This live feed shows all institutional transactions in real time.
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)